Ernexa Therapeutics (ERNA) to Release Quarterly Earnings on Wednesday

Posted by Geri Gentry on Aug 5th, 2026

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) is anticipated to issue its results after the market closes on Wednesday, August 12th. Analysts expect the company to announce earnings of ($3.30) per share for the quarter.

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($6.95) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). On average, analysts expect Ernexa Therapeutics to post $-18 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ernexa Therapeutics Trading Up 28.1%

Shares of ERNA opened at $4.42 on Wednesday. Ernexa Therapeutics has a 52 week low of $3.18 and a 52 week high of $71.50. The firm has a market cap of $5.17 million, a price-to-earnings ratio of -0.17 and a beta of 2.57. The stock has a 50 day moving average of $6.29 and a 200-day moving average of $9.25.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Friday, July 17th. Finally, Brookline Capital Markets assumed coverage on shares of Ernexa Therapeutics in a report on Thursday, May 7th. They set a “buy” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $30.00.

Read Our Latest Stock Analysis on ERNA

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is owned by hedge funds and other institutional investors.

About Ernexa Therapeutics

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.